
|Videos|March 25, 2014
Augmenting the Benefit of Hormonal Therapy in Breast Cancer
Author(s)Debu Tripathy, MD
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses augmenting the benefit of hormonal therapy in breast cancer.
Advertisement
Clinical Pearls
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses augmenting the benefit of hormonal therapy in breast cancer.
- The CDK4/6 inhibitor palbociclib has yielded exciting preliminarily results
- In a phase II study, the combination of palbociclib and letrozole tripled PFS compared with letrozole alone (26.1 months versus 7.5 months)
- The HDAC inhibitor entinostat plus hormonal therapy was found to improve survival in a phase II study
- Src inhibition showed benefit in a trial
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at SABCS 2025
2
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
3
Considering Role of PD-L1 CPS in Frontline Gastric Cancer Treatment
4
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
5








































